Defence Therapeutics Inc.
DTC
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 80.30% | -2.21% | |||
| Depreciation & Amortization | -3.15% | -2.31% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.44% | 16.60% | |||
| Operating Income | -29.44% | -16.60% | |||
| Income Before Tax | -15.36% | -29.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.36% | -29.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.36% | -29.24% | |||
| EBIT | -29.44% | -16.60% | |||
| EBITDA | -28.91% | -17.05% | |||
| EPS Basic | -8.87% | -26.53% | |||
| Normalized Basic EPS | -25.64% | -27.87% | |||
| EPS Diluted | -8.87% | -26.53% | |||
| Normalized Diluted EPS | -25.64% | -27.87% | |||
| Average Basic Shares Outstanding | 6.53% | 1.45% | |||
| Average Diluted Shares Outstanding | 6.53% | 1.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||